ADHD, One Name for Many Different Minds

Why "everyone is different" is the starting point, not a footnote.

Attention deficit hyperactivity disorder is defined by persistent, impairing inattention and disorganisation together with hyperactivity and impulsivity, usually beginning early in childhood and affecting somewhere around 5 to 10 percent of school age children. That single sentence hides an enormous amount of variation. The diagnosis is built from two symptom lists, and a person needs only a subset of items from each to qualify. Two people can both meet criteria and share almost no symptoms in common. This is why clinicians talk about presentations rather than one uniform disorder: predominantly inattentive, predominantly hyperactive and impulsive, and combined.

The variation goes deeper than the checklist. ADHD travels with other conditions far more often than not. Anxiety, depression, oppositional and conduct problems, learning difficulties, and later substance use are all common companions, and each one reshapes how the underlying attention problem looks from the outside. It also changes across a lifetime. The visibly restless six year old often becomes a teenager whose hyperactivity has gone underground into a constant inner churn, and then an adult who looks calm but cannot finish a tax return. Girls and women have historically been missed because the loud, disruptive stereotype was built around boys, while a quietly inattentive girl gets labelled a daydreamer and slips through.

This is where Gabor Maté's Scattered Minds made its contribution. Maté argued that ADHD is best understood as a spectrum of self regulation rather than a fixed, all or nothing category, and he pushed hard against the idea that it always looks like a bouncing, disruptive child. His central portrait is the quiet, dreamy, "tuned out" person who is just as impaired as the hyperactive one but attracts none of the concern, because their difficulty is invisible. He emphasised the emotional side that the diagnostic manuals underplay: heightened sensitivity, a raw response to rejection, and difficulty regulating feeling as much as attention. Drawing on his own ADHD, he framed the condition as something lived from the inside, a way of being wired rather than a list of behaviours observed from the outside.

It is worth being fair but critical about where Maté sits. His framework leans heavily on early emotional environment and attachment as causes, and that emphasis is contested. The behavioural genetics evidence is consistent and strong: ADHD is one of the more heritable psychiatric conditions, with twin studies putting heritability in the region of 70 to 80 percent. Most researchers now see it as a highly polygenic, neurodevelopmental condition in which environment shapes outcomes and severity rather than being the primary cause. Maté's clinical descriptions of how differently ADHD manifests are valuable and humane. His causal story is one interpretation, and a reader is better served treating the vivid portraits as the durable part and the environmental theory as the debatable part.

The practical takeaway is simple and important. The same underlying problem surfaces differently depending on the person, their age, their sex, their other conditions, and their circumstances, so the label is where understanding starts, not where it ends.

The neuroscience, networks and chemistry rather than a single broken part

There is no lesion you can point to on a scan and no blood test that confirms ADHD. Diagnosis remains clinical. What the research does show is a pattern of differences in how certain brain networks are wired, how they mature, and how they are tuned chemically.

The chemistry. Two neurotransmitters sit at the centre of most models: dopamine and noradrenaline, the catecholamines. Dopamine matters for motivation, reward anticipation, and the signalling that tags which stimuli deserve attention. Noradrenaline matters for arousal, alertness, and the gain on incoming signals. The dominant idea is not simply "too little dopamine" but rather a system that is tuned suboptimally. Volkow and colleagues, using PET imaging, found evidence of a blunted dopamine reward pathway in people with ADHD, with reduced dopamine signalling in striatal regions tied to motivation. Reviews of the neuroimaging literature describe blunted striatal dopamine release alongside disrupted communication between the anterior cingulate cortex, the striatum, and the prefrontal cortex. That circuitry is exactly the machinery you would expect to matter for holding goals in mind, filtering distraction, and inhibiting an impulse.

The circuits. The prefrontal cortex is the region most consistently implicated, working in loops with the basal ganglia and the anterior cingulate. These frontostriatal circuits carry out what psychologists call executive function: working memory, response inhibition, sustained attention, and the moment to moment regulation of behaviour toward a goal. When this system runs weakly or noisily, the downstream result is the recognisable ADHD picture, losing the thread of a task, acting before thinking, and struggling to get started on things that are not immediately rewarding.

Attention networks and the wandering mind. A useful piece of the story is the interplay between the brain's task focused networks and the default mode network, the system active when the mind is idle and self referential. In ADHD this idling network tends to intrude during tasks that demand focus, which fits the lived experience of the mind drifting off mid sentence. Stimulant medication appears to help partly by strengthening the task positive attention networks and quieting task irrelevant activity, which is how Swanson, Baler and Volkow summarised a decade of imaging work.

Development. Structural imaging suggests the ADHD brain often follows a delayed maturational trajectory, with certain cortical regions reaching peak thickness a few years later than in peers, rather than being permanently abnormal. This helps explain why some, though not all, people see symptoms soften with age.

Genetics. The high heritability noted earlier is not carried by one gene. Many common variants each nudge risk upward, several of them involving dopamine signalling and neurodevelopment. This polygenic architecture is part of why the condition is so heterogeneous. Different combinations of small effects produce different flavours of the same broad problem.

The honest summary is that we have a coherent and well supported model, catecholamine tuning within frontostriatal networks that mature late, but not a complete mechanistic account. Much of what we believe about mechanism is inferred backwards from imaging plus the observation of what medications do.

Current medications, what they do and how we think they work

ADHD medications fall into two broad groups, stimulants and nonstimulants. None of them cure anything. They adjust catecholamine signalling while they are active in the body, which is why symptoms return once a dose wears off.

Stimulants, first line for most people

Stimulants are the most effective and best evidenced treatments, and they come in two chemical families.

Methylphenidate (Ritalin, Concerta, Medikinet, Jornay PM and others) works mainly by blocking the transporters that clear dopamine and noradrenaline out of the synapse, the dopamine transporter and the noradrenaline transporter. By slowing reuptake, more of each neurotransmitter lingers where neurons can use it. PET studies by Volkow's group showed that methylphenidate raises extracellular dopamine in the basal ganglia and anterior cingulate, which lines up neatly with the circuits described above. Formulations differ mostly in delivery. Ritalin is short acting, Concerta releases across the day, and Jornay PM is taken at night so that coverage is present on waking.

Amphetamines (Adderall, the prodrug lisdexamfetamine sold as Vyvanse in the US and Elvanse in the UK, the patch Xelstrym, and related agents) do everything methylphenidate does and one thing more. As well as blocking reuptake, they are taken up into the neuron and actively push dopamine and noradrenaline back out into the synapse, reversing the transporters and interfering with the packaging and breakdown of the transmitter inside the cell. The net effect is a stronger increase in available catecholamines. Newer stimulant options include dexmethylphenidate and the combination product Azstarys, which pairs a dexmethylphenidate prodrug with immediate release drug for smoother delivery.

The apparent paradox. People are often puzzled that a stimulant calms someone with ADHD. The resolution lies in the inverted U shaped relationship between catecholamine levels and prefrontal function. Both too little and too much dopamine and noradrenaline degrade prefrontal performance. An untreated ADHD prefrontal cortex appears to sit on the low side of that curve, so a carefully dosed stimulant moves it toward the optimum, improving the signal to noise ratio of neural activity. The result is better focus and less impulsivity, which reads as calm.

Nonstimulants

These are used when stimulants are not tolerated, not wanted, insufficiently effective, or when a comorbid condition tips the balance. Up to around 30 percent of people do not respond well to stimulants, so this group matters. There are currently five nonstimulants approved for ADHD.

Atomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor. Blocking the noradrenaline transporter raises noradrenaline throughout the relevant circuits, and, importantly, it also raises dopamine specifically in the prefrontal cortex. That happens because the prefrontal cortex has very few dopamine transporters of its own, so dopamine there is mopped up largely by the noradrenaline transporter. Block that transporter and prefrontal dopamine rises too, without directly flooding the striatal reward pathway, which is why atomoxetine carries little abuse potential. Its main drawback is speed. It builds up over weeks rather than working within an hour. Placebo controlled trials by Michelson and colleagues established its efficacy in adults.

Viloxazine (Qelbree) is a newer nonstimulant approved in 2021 for children and adults. It is primarily a noradrenaline reuptake inhibitor with additional serotonergic modulation, and it is often considered when emotional dysregulation or anxiety sit alongside the ADHD. Like atomoxetine, it is a daily medication rather than an on demand one.

Guanfacine (Intuniv) and clonidine (Kapvay, and the newer once daily liquid Onyda XR approved in 2024) work by a completely different route. They are alpha 2 adrenergic agonists. Rather than raising catecholamine levels, they act on receptors on prefrontal neurons themselves, strengthening the connectivity of prefrontal networks and effectively boosting the signal side of the signal to noise problem. Guanfacine is the more selective of the two and tends to be less sedating, while clonidine's broader action makes it more calming and useful where sleep or tics are also in play. Both are used alone or added to a stimulant.

Beyond the approved five, clinicians sometimes reach off label for bupropion, which has noradrenergic and dopaminergic activity, or older tricyclic antidepressants, particularly in adults with co-occurring depression.

On the horizon

The main late stage candidate is centanafadine, a triple reuptake inhibitor that raises noradrenaline, dopamine and serotonin. A new drug application has been submitted and phase 3 trials in adults and children reported meaningful symptom improvement, but as of late 2025 it is not yet approved. If it clears review it would be the first triple reuptake inhibitor for the condition.

The honest caveat on mechanism

It is worth stating plainly. The signal to noise and inverted U account is a model that fits the data well, not a proven and complete explanation. We know what these drugs do at the level of transporters and receptors, and we can watch some of their effects on imaging, but the leap from "raises prefrontal catecholamines" to "improves a specific person's attention" still involves inference. Response varies widely between individuals, dosing is a process of trial and adjustment, and the same medication can transform one person and do little for another. That unpredictability is the clinical mirror of the heterogeneity we started with.

Pulling it together

The most useful thing to hold onto is the thread running through all three sections. ADHD is genuinely variable at every level. It looks different from person to person, which Maté captured in his portraits of the tuned out as well as the hyperactive. It arises from tunable networks rather than a single broken part, which is why the neuroscience is a story about chemistry and circuits and maturation rather than a lesion. And it is treated by nudging that chemistry back toward an optimum, which is why the medications adjust rather than cure, and why finding the right one is so often a matter of patient trial. One name, many minds.

The name fits everyone and describes no one.

Sources drawn on